LTI0
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloi… Read more
LTI0 (LTI0) - Total Liabilities
Latest total liabilities as of September 2025: €25.79 Million EUR
Based on the latest financial reports, LTI0 (LTI0) has total liabilities worth €25.79 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
LTI0 - Total Liabilities Trend (2021–2024)
This chart illustrates how LTI0's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
LTI0 Competitors by Total Liabilities
The table below lists competitors of LTI0 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
InnSuites Hospitality Trust
NYSE MKT:IHT
|
USA | $14.04 Million |
|
INVO Bioscience Inc
NASDAQ:INVO
|
USA | $17.04 Million |
|
Joy Industrial Co., Ltd.
TWO:4559
|
Taiwan | NT$1.21 Billion |
|
Sulliden Minerals SA
TO:SMC
|
Canada | CA$2.72 Million |
|
Hayasa Metals Inc.
V:HAY
|
Canada | CA$634.34K |
|
Pure Biologics Spólka Akcyjna
WAR:PUR
|
Poland | zł20.72 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down LTI0's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LTI0's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LTI0 (2021–2024)
The table below shows the annual total liabilities of LTI0 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €14.67 Million | -7.68% |
| 2023-12-31 | €15.89 Million | +19.60% |
| 2022-12-31 | €13.29 Million | +60.28% |
| 2021-12-31 | €8.29 Million | -- |